Published in Enferm Infecc Microbiol Clin on June 30, 2008
Managing dyslipidemia in HIV/AIDS patients: challenges and solutions. HIV AIDS (Auckl) (2014) 0.80
New options in the treatment of lipid disorders in HIV-infected patients. Open AIDS J (2009) 0.79
Lipid lowering efficacy and safety of Ezetimibe combined with rosuvastatin compared with titrating rosuvastatin monotherapy in HIV-positive patients. Lipids Health Dis (2015) 0.75
In vivo effect of statins on the expression of the HIV co-receptors CCR5 and CXCR4. AIDS Res Ther (2013) 0.75
Once-daily darunavir/ritonavir vs. lopinavir/ritonavir in treatment-naive, HIV-1-infected patients: 96-week analysis. AIDS (2009) 2.15
Week 96 efficacy and safety of rilpivirine in treatment-naive, HIV-1 patients in two Phase III randomized trials. AIDS (2013) 1.29
Randomized trial to evaluate indinavir/ritonavir versus saquinavir/ritonavir in human immunodeficiency virus type 1-infected patients: the MaxCmin1 Trial. J Infect Dis (2003) 1.25
The safety and efficacy of switching stavudine to tenofovir df in combination with lamivudine and efavirenz in hiv-1-infected patients: three-year follow-up after switching therapy. HIV Clin Trials (2007) 1.12
Sex risk practices among HIV-positive individuals in Buenos Aires, Argentina. AIDS Patient Care STDS (2009) 0.94
Meningitis due to vancomycin-resistant Enterococcus faecium successfully treated with combined intravenous and intraventricular chloramphenicol. J Clin Microbiol (2005) 0.91
Efficacy and safety of entecavir for chronic HBV in HIV/HBV coinfected patients receiving lamivudine as part of antiretroviral therapy. AIDS (2008) 0.88
Efficacy and tolerability of 10-day monotherapy with apricitabine in antiretroviral-naive, HIV-infected patients. AIDS (2006) 0.87
Nevirapine-associated toxicity in clinical practice in Buenos Aires, Argentina. J Int Assoc Physicians AIDS Care (Chic) (2010) 0.85
Patient-provider perceptions on engagement in HIV care in Argentina. AIDS Care (2013) 0.84
[Chagasic cardiopathy in endemic area versus sporadically infected patients]. Rev Saude Publica (2002) 0.83
Safe treatment interruptions in patients with nadir CD4 counts of more than 350 cells/microL: a randomized trial. J Acquir Immune Defic Syndr (2006) 0.82
CD4 cell count among HIV-infected patients with an AIDS-defining disease: higher count in patients coinfected than in those not coinfected with human T-cell lymphotropic virus type I. J Acquir Immune Defic Syndr (2003) 0.80
Etravirine: clinical review of a treatment option for HIV type-1-infected patients with non-nucleoside reverse transcriptase inhibitor resistance. Antivir Ther (2010) 0.79
[Osteonecrosis in HIV-infected patients]. Medicina (B Aires) (2004) 0.78
[Incidence variation in malignancies associated or not with AIDS at an outpatient care center, 1997-2005]. Medicina (B Aires) (2007) 0.77
[Primary HIV resistance in Buenos Aires metropolitan area]. Medicina (B Aires) (2015) 0.77
Pilot, randomized study assessing safety, tolerability and efficacy of simplified LPV/r maintenance therapy in HIV patients on the 1 PI-based regimen. PLoS One (2011) 0.77
Multiple-dose pharmacokinetics of apricitabine, a novel nucleoside reverse transcriptase inhibitor, in patients with HIV-1 infection. Clin Drug Investig (2008) 0.75
[COGNITIVE SCREENING IN HIV-1 INFECTED YOUNG ADULTS AT BUENOS AIRES. PRELIMINARY DATA]. Vertex (2015) 0.75